Monsanto Articles
Synthelabo Strong In Europe And Expanding
30 October 1995
Monsanto's Japanese R&D Unit For Sale
18 September 1995
US Economic Slowdown Affects Larger Firms
7 August 1995
Sandoz Acquires Genetic Therapy For $295 Million
17 July 1995
Searle/Monsanto mergers
10 July 1995
GD Searle takes on Japan
12 June 1995
NEW YORK STOCK COMMENT
9 January 1995
Monsanto Acquisition
2 January 1995
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
RDL, The Rising Star In Contract Detailing
24 October 1994
Xenova "Outstanding Long-Term Investment"
15 August 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
SERLE IS SEEKING PARTNERSHIPS
11 July 1994
ROBERTS COMPLETES ACQUISITION
16 May 1994
US CHEMICAL/DRUG COs SHOW 1st QTR GROWTH
9 May 1994
NEW YORK STOCK COMMENT
18 April 1994
IVAX SUFFERS OVER GENERIC THREAT
11 April 1994
N AMERICAN PHARMA MARKET STUDIED
28 February 1994
SEARLE SIGNS CHINESE AGREEMENT
21 February 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
1992 SEES SMALLER COMPANY MERGERS
10 January 1994
US GOV'T STARTS NATURAL DRUG DISCOVERY PROJECT
20 December 1993
ASTRA LEADING PERFORMER IN CHEM INSIGHT ANALYSIS
29 November 1993
MONSANTO SALE
25 October 1993
US 3rd QTR RESULTS MIXED AS DRUG IND CUTS BACK
25 October 1993
SEARLE SELLS BELGIAN FACILITY
20 September 1993
TOKYO STOCK COMMENT
13 September 1993
ADVANCES BY US DRUG COMPANIES IN 2nd QTR
26 July 1993
PHARMA DIRECTION FOR BRITISH BIO-TECHNOLOGY
19 July 1993
NOVEL HIV ANTIVIRALS IN DEVELOPMENT
28 June 1993
OPPORTUNITIES IN UK BIOSCIENCE SECTOR
21 June 1993
ADVANCES AND SLOW DOWNS IN US 1st QTRS
3 May 1993
AMERICAN HOME HAS CONFIDENCE FOR 1993
12 April 1993
MERCK & CO "MOST ADMIRED" US FIRM
29 March 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
MONSANTO PURCHASE
25 January 1993
SCHIAPPARELI AND SEARLE SPLIT
4 January 1993
PROMOTIONS AT MONSANTO
14 December 1992
ASTRA IS CHEM INSIGHT'S STAR PERFORMER
14 December 1992
US CHEMICAL/PHARMA COS' POOR PERFORMANCE
9 November 1992
FDA APPRO FOR SEARLE'S DAYPRO
9 November 1992
MONSANTO NEW DIRECTOR
2 November 1992
CHEMICAL INSIGHT INDUSTRIAL RANKINGS
5 October 1992
GOOD GROWTH FOR US COMPANIESCONTINUES FOR US COs
3 August 1992
New York: Stock comment
22 June 1992
Stock Comment:SPECTRUM
15 June 1992
GOOD 1st QTRs for ALZA, IMMUNEX AND MYLAN
4 May 1992
LOREX' AMBIEN SET FOR US APPROVAL?
4 May 1992
US PRICE DISCOUNTING
17 February 1992
STOCK MARKET COMMENTARY: NEW YORK
3 February 1992
GOOD 1991 RESULTS FOR MERCK AND FOREST LABS
3 February 1992
COMPETITION IN USA FOR NUTRASWEET?
3 February 1992
ALZHEIMER'S DISEASE: US CONCERN
27 January 1992
FEWER ACQUISITIONS AND MERGERS IN 1991
6 January 1992
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
